AbbVie unit wins ITC trade secret case against Evolus
AbbVie's (ABBV) Allergan unit won an order to block Evolus (EOLS) and partner Daewoong from importing Jeuveau into the U.S. for 21 months, reported Bloomberg's Susan Decker and Christopher Yasiejko. Jeuveau is a rival to Allergan's wrinkle treatment Botox. Following the report, Evolus shares are down 46c, or 11%, to $3.57 in afternoon trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.